Beyond black-box QSAR: Explainable AI and uncertainty in endocrine screening

Traditional quantitative structure-activity relationship (QSAR) and ADMET tools have been used in chemical discovery for decades, yet their adoption in high-stakes stage-gate decisions and regulatory defense remains constrained by a fundamental limitation: opaque predictions without reliability bounds.

When a conventional predictive script outputs a single binary label or uncalibrated number for endocrine disruption risk, neither the medicinal chemist nor the regulatory reviewer has the evidence required to make a confident capital decision.

Three Requirements for Defensible In Silico Decisions

To transform computational toxicology from an exploratory calculation into an operational decision tool, predictions must answer three distinct questions simultaneously:

• What is the calibrated risk priority? Rather than isolated endpoints, R&D teams need probability scores that rank candidate cohorts so wet-lab budgets focus strictly on the highest-confidence leads.
• How reliable is the model for this specific chemical space? Every predictive model has boundaries. Quantifying prediction uncertainty and structural coverage prevents teams from discarding promising novel scaffolds due to out-of-domain false positives.
• Which structural features drive the alert? Explainable AI (XAI) bridges the gap between statistical inference and chemical intuition by highlighting the specific molecular descriptors and substructures contributing to a predicted endocrine liability.

Unifying Activity, Toxicity, and Exposure

In real-world product development, toxicity cannot be evaluated in a vacuum. A candidate molecule’s viability depends on the interplay between its intended biological activity, its off-target endocrine profile, and its expected exposure context.

“Replacing disconnected QSAR spreadsheets with an integrated, explainable workflow reduces both the time and the cost per decision before bench synthesis.”

By unifying molecular visualization, uncertainty metrics, and explainable feature attribution into a single multi-tenant workspace, EndoXplain enables discovery and safety teams to iterate on molecular structures upstream—before committing months of wet-lab synthesis and bioassay expenditure.